Consistent with previous studies, we observed recurrent NTRK1 and NTRK3 fusions in papillary thyroid cancer and glioblastoma, but also identified a number of novel NTRK2 fusions in head and neck squamous cell carcinoma (PAN3–NTRK2), low-grade glioma (AFAP1–NTRK2) and lung adenocarcinoma (TRIM24–NTRK2) (Fig. 1, Supplementary Fig. 8). This evidence concerns the gene TRIM24 and central nervous system cancer.